Oncocyte Corporation — Q1 2022 Form 10-Q
Entity note: The filing identifies the registrant as Oncocyte Corporation, not Insight Molecular Diagnostics Inc. The unaudited reporting period is the three months ended March 31, 2022; comparisons are with Q1 2021 unless otherwise noted. Amounts below are in U.S. dollars.
Business context
Oncocyte develops and commercializes molecular diagnostic tests and provides pharmaceutical services. Its products and pipeline include DetermaRx, DetermaIO, DetermaTx and tests acquired with Chronix. Revenue is generated mainly from DetermaRx testing and Pharma Services. DetermaRx has Medicare and Medicare Advantage reimbursement; the filing describes DetermaIO as available for research use and drug-development purposes, not yet as a clinical test.
Financial results and position
- Revenue: $1.424 million, up 27% from $1.124 million. DetermaRx revenue was $1.004 million (+66%); Pharma Services was $380,000 (−26%); licensing was $40,000. DetermaRx represented 70% of revenue, versus 54% a year earlier.
- Gross profit and margin: Gross loss was $533,000, compared with gross profit of $79,000. Gross margin was approximately −37% versus 7%. Cost of revenue, including acquired-intangible amortization, rose 87% to $1.957 million.
- Operating expenses and loss: Research and development was $5.128 million (+53%), sales and marketing $3.237 million (+44%), and general and administrative $5.653 million (+19%). Operating loss was $9.895 million, versus $11.360 million. This comparison included a $4.656 million gain from the fair-value change in contingent consideration in 2022, versus a $1.060 million loss in 2021.
- Net loss: $10.291 million, or $0.11 per share, versus $3.919 million, or $0.05 per share. The prior-year quarter included a $7.564 million income-tax benefit related to the Razor acquisition; no tax benefit was recorded in Q1 2022.
- Cash flow: Operating cash use was $13.277 million, up from $9.835 million. Investing cash use was $1.561 million, mainly for construction and equipment. Financing cash use was $355,000. Cash, cash equivalents and restricted cash declined $15.193 million to $22.112 million; cash and cash equivalents alone were $20.412 million.
- Liquidity and balance sheet: Current assets were $24.623 million and current liabilities $13.955 million. Total assets were $146.273 million, total liabilities $89.306 million, and shareholders’ equity $56.967 million. Accumulated deficit was $198.065 million. Marketable equity securities were valued at $574,000.
- Debt and other obligations: Current loans payable, net of financing costs, were $945,000. The Silicon Valley Bank loan maturity had been extended to September 30, 2022; Oncocyte said it was compliant and eligible, but had not drawn, an additional $2 million tranche. Lease liabilities totaled approximately $4.176 million. Contingent consideration liabilities totaled $72.025 million, including $64.605 million associated with Chronix and $7.420 million with Insight.
Changes, outlook and risks
- DetermaRx growth and new licensing revenue lifted total revenue, while Pharma Services revenue declined. Higher testing, laboratory and amortization costs contributed to the gross loss.
- Management attributed higher R&D spending to staffing, product development and clinical trials; it expects significant R&D and sales and marketing spending to continue. No specific revenue, earnings or cash-flow guidance was provided.
- Management said cash, cash equivalents and marketable securities at March 31, 2022 were expected to fund current operations for at least 12 months from issuance of the statements. The company also stated that it would need additional capital until operating revenue can cover expenses.
- Subsequent financing: On April 19, 2022, the company completed an underwritten common-stock-and-warrant offering and received approximately $32.8 million net. A separate Series A convertible preferred-stock offering was also disclosed, with $10 million aggregate gross proceeds planned in two tranches. The preferred stock carries a 6% cumulative dividend, redemption provisions, and a minimum-cash covenant; its terms may affect liquidity and future dilution.
- Commercial and operating risks: Medicare or private-payer coverage, test adoption, clinical development, reimbursement rates and ability to raise capital remain uncertain. COVID-19 could defer surgeries and clinical trials, constrain marketing and disrupt suppliers or operations. Revenue is concentrated: Medicare and Medicare Advantage together represented 65% of Q1 2022 revenue; one Pharma Services customer represented 14%.
- Unusual items and contingencies: The $4.656 million contingent-consideration gain reflects a net fair-value decrease, primarily from revised timing estimates and discount rates; these estimates rely on significant unobservable inputs. The filing reports no material litigation and no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm the registrant identity: this filing is for Oncocyte Corporation, notwithstanding the request metadata naming Insight Molecular Diagnostics Inc.
- Review the April 2022 equity and preferred-stock financings, including actual proceeds, dilution, warrant exercise terms, preferred-stock redemption obligations and cash-minimum covenant.
- Track cash burn against management’s runway statement, the September 2022 bank-loan maturity and any use of the available $2 million loan tranche.
- Assess DetermaRx test volumes, payer collections and reimbursement coverage, alongside the decline in Pharma Services revenue and customer concentration.
- Monitor clinical, regulatory and commercialization milestones for pipeline tests, and changes in the large Level 3 contingent-consideration liabilities.